{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T19:59:54Z","timestamp":1783799994059,"version":"3.55.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were collected retrospectively through 4 TB programs using a standardized abstraction tool. Data were analyzed using univariate methods. Adverse events were graded using the Common Terminology Criteria for Adverse Events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 14 patients, 7 (50%) had MDR, 4 (29%) had pre\u2013extensively drug-resistant (XDR), and 3 (21%) had XDR TB. All had pulmonary TB, 5 (36%) had pulmonary and extrapulmonary TB, and 9\/13 (69%) were smear positive. One patient (7%) had HIV coinfection, 5 (36%) had diabetes mellitus, and 5\/14 (36%) had previous treatment TB. All patients were non\u2013US-born and 5\/14 (36%) had private insurance. All patients achieved sputum culture conversion within a mean of 71 days (26\u2013116); 5 after starting bedaquiline. Twelve (86%) completed treatment and 1 (7%) moved out of the country. One patient (7%) had QTc prolongation &amp;gt;500 milliseconds and died 20 months after discontinuing bedaquiline of a cause not attributable to the drug. Common adverse events were peripheral neuropathy 7\/14 (50%), not customarily associated with bedaquiline use, and QTc prolongation 6\/14 (43%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Of 14 patients, 1 (7%) had an adverse event necessitating bedaquiline discontinuation. Safety, culture conversion, and treatment completion in this series (7%) support use of bedaquiline for the treatment of MDR\/XDR TB.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz914","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T11:36:44Z","timestamp":1568806604000},"page":"1010-1016","source":"Crossref","is-referenced-by-count":36,"title":["Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States"],"prefix":"10.1093","volume":"71","author":[{"given":"Sundari","family":"Mase","sequence":"first","affiliation":[{"name":"World Health Organization, India Country Office, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Chorba","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Parks","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Belanger","sequence":"additional","affiliation":[{"name":"Tuberculosis Control Branch, California Department of Public Health, Richmond, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Dworkin","sequence":"additional","affiliation":[{"name":"Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seaworth","sequence":"additional","affiliation":[{"name":"Heartland National Tuberculosis Center, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Warkentin","sequence":"additional","affiliation":[{"name":"Tuberculosis Elimination Program, Tennessee Department of Health, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-1890","authenticated-orcid":false,"given":"Pennan","family":"Barry","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"},{"name":"Tuberculosis Control Branch, California Department of Public Health, Richmond, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,26]]},"reference":[{"key":"2020081419065142200_CIT0001","volume-title":"Drug-resistant tuberculosis: a survival guide for clinicians","author":"Francis","year":"2011","edition":"2"},{"key":"2020081419065142200_CIT0002","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1183\/09031936.00136312","article-title":"Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis","volume":"42","author":"Migliori","year":"2013","journal-title":"Eur Respir J"},{"key":"2020081419065142200_CIT0003","volume-title":"Policy update: Xpert MTB\/RIF assays for the diagnosis of pulmonary and extrapulmonary TB in adults and children. WHO\/HTM\/TB\/2013.6","author":"World Health Organization","year":"2013"},{"key":"2020081419065142200_CIT0004","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4103\/lungindia.lungindia_98_17","article-title":"Multidrug-resistant tuberculosis\/rifampicin-resistant tuberculosis: principles of management","volume":"35","author":"Prasad","year":"2018","journal-title":"Lung India"},{"key":"2020081419065142200_CIT0005","volume-title":"World Health Organization global tuberculosis report 2018","year":"2018"},{"key":"2020081419065142200_CIT0006","volume-title":"Reported tuberculosis in the United States, 2017","author":"Centers for Disease Control and Prevention","year":"2018"},{"key":"2020081419065142200_CIT0007","doi-asserted-by":"crossref","first-page":"1602308","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"Falzon","year":"2017","journal-title":"Eur Respir J"},{"key":"2020081419065142200_CIT0008","volume-title":"The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance","author":"World Health Organization","year":"2013"},{"key":"2020081419065142200_CIT0009","volume-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance","author":"World Health Organization","year":"2014"},{"key":"2020081419065142200_CIT0010","doi-asserted-by":"crossref","first-page":"1700061","DOI":"10.1183\/13993003.00061-2017","article-title":"Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses","volume":"50","author":"Ahmad Khan","year":"2017","journal-title":"Eur Respir J"},{"key":"2020081419065142200_CIT0011","article-title":"WHO consolidated guidelines on drug-resistant TB treatment","author":"World Health Organization"},{"key":"2020081419065142200_CIT0012","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"2020081419065142200_CIT0013","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2020081419065142200_CIT0014","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40265-014-0241-5","article-title":"Delamanid: first global approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"2020081419065142200_CIT0015","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N Engl J Med"},{"key":"2020081419065142200_CIT0016","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.06126-11","article-title":"Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance","volume":"56","author":"Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081419065142200_CIT0017","volume-title":"FDA accelerated approval letter to Janssen Research and Development","author":"Cox","year":"2012"},{"key":"2020081419065142200_CIT0018","first-page":"1","article-title":"Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020081419065142200_CIT0019","doi-asserted-by":"crossref","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"},{"key":"2020081419065142200_CIT0020","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1183\/13993003.01891-2015","article-title":"Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence","volume":"47","author":"Pontali","year":"2016","journal-title":"Eur Respir J"},{"key":"2020081419065142200_CIT0021","doi-asserted-by":"crossref","first-page":"1700146","DOI":"10.1183\/13993003.00146-2017","article-title":"Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline","volume":"49","author":"Pontali","year":"2017","journal-title":"Eur Respir J"},{"key":"2020081419065142200_CIT0022","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3201\/eid2005.131037","article-title":"Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005\u20132007","volume":"20","author":"Marks","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2020081419065142200_CIT0023","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5588\/pha.17.0091","article-title":"The California Multidrug-Resistant Tuberculosis Consult Service: a partnership of state and local programs","volume":"8","author":"Shah","year":"2018","journal-title":"Public Health Action"},{"key":"2020081419065142200_CIT0024","first-page":"1","article-title":"Introduction and evaluation of multidrug-resistant tuberculosis supplemental","volume":"15","author":"Belanger","year":"2019","journal-title":"J Clin Tuberc Other Infect Dis"},{"key":"2020081419065142200_CIT0025","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(13)62675-6","article-title":"Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study","volume":"383","author":"Pietersen","year":"2014","journal-title":"Lancet"},{"key":"2020081419065142200_CIT0026","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1001\/jama.300.18.2153","article-title":"Extensively drug-resistant tuberculosis in the United States, 1993\u20132007","volume":"300","author":"Shah","year":"2008","journal-title":"JAMA"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz914\/30665967\/ciz914.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/4\/1010\/33653997\/ciz914.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/4\/1010\/33653997\/ciz914.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T23:15:06Z","timestamp":1597446906000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/4\/1010\/5574390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,26]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,9,26]]},"published-print":{"date-parts":[[2020,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz914","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8,15]]},"published":{"date-parts":[[2019,9,26]]}}}